Y-mAbs Therapeutics Inc (NAS:YMAB)
$ 12.14 -0.59 (-4.63%) Market Cap: 532.73 Mil Enterprise Value: 484.06 Mil PE Ratio: 0 PB Ratio: 5.37 GF Score: 56/100

Y-mAbs Therapeutics Inc To Host Annual Research and Development Day Transcript

Dec 14, 2022 / 02:00PM GMT
Release Date Price: $5.08 (+3.46%)
Unidentified Company Representative

Welcome, everybody, to the 2022 Y-mAbs R&D Day. We will have the presentations by management over the next 1.5 hours, and we're very excited to share their plans. Please note the disclaimer here and forward-looking statements, and you can read them and check the website and the SEC filings.

At this point, I'd like to invite Thomas Gad, Founder, Interim CEO, Head of Business Development and Strategy and overall inspirational guy [to move into the slides].

Thomas Gad
Y-mAbs Therapeutics, Inc. - Founder, Interim CEO, President, Head of Business Development & Strategy and Director

Thanks, [Sanjay]. Thanks. Good morning, everyone, and thank you for being here today and spending time with Y-mAbs. We are in an exciting period of time, a little bit overshadowed by our ODAC vote, but we will manage through that as well. So I'll start with a short update, company update. Then we'll hear from Steen Lisby, our Chief Scientific Officer, who will focus on our exciting SADA development. And after that, we will hear from Vignesh,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot